title: Risk and liabilities of prescribing compounded medications.
abstract: Complications resulting from the use of compounded medications have become a troubling trend nationwide. There is a significant potential for patients to suffer serious harm from the use of substandard medications prepared by compounding pharmacies, and the reality of this problem has been demonstrated in several well-publicized incidences of serious medical complications, including patient deaths, that directly resulted from the use of medications prepared at compounding pharmacies. Unlike US Food and Drug Administration (FDA)-approved drugs, compounded products are not required to meet evidentiary standards for establishing safety and efficacy. Moreover, these products are not held to Good Manufacturing Practices, which require regular inspections, quality control testing, and rejection of material not meeting specifications. Physicians, as well as other prescribers, need to be aware that when a patient suffers harm from using a compounded medication, those injured patients may bring negligence and malpractice claims, not only against the pharmacy and the pharmacist responsible for preparing the medication, but also against the prescribing physician and the physician’s practice. Consequently, the best way for physicians to manage professional risk and avoid both litigation and potential negative patient outcomes related to compounded pharmaceuticals is to not use these products if there is an FDA-approved product available. However, if the use of a compounded medication is medically necessary, then physicians should adhere to the FDA guidance concerning traditional compounding. Moreover, it would be prudent for any physician who intends to either resell or participate in the distribution of compounded products beyond the direct treatment of their patients to consider obtaining the appropriate insurance coverage for this activity.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Randell
authors.forename: Phillip J
authors.initials: PJ
authors.lastname: Duffy
mesh_terms: D000077713:17 alpha-Hydroxyprogesterone Caproate; D017277:Drug Approval; D004339:Drug Compounding / Q000009:adverse effects / Q000592:standards; D006801:Humans; D006908:Hydroxyprogesterones / Q000008:administration & dosage / Q000592:standards; D007351:Insurance, Liability; D016365:Liability, Legal; D008318:Malpractice; D009774:Obstetrics / Q000331:legislation & jurisprudence; D010818:Practice Patterns, Physicians' / Q000331:legislation & jurisprudence; D011372:Progestins / Q000008:administration & dosage / Q000592:standards; D018570:Risk Assessment; D014481:United States
chemical_list: D006908:Hydroxyprogesterones; D011372:Progestins; D000077713:17 alpha-Hydroxyprogesterone Caproate